181 related articles for article (PubMed ID: 31013454)
1. In New-Onset Diabetes Mellitus, Metformin Reduces Fat Accumulation in the Liver, But Not in the Pancreas or Pericardium.
Zsóri G; Illés D; Ivány E; Kosár K; Holzinger G; Tajti M; Pálinkás E; Szabovik G; Nagy A; Palkó A; Czakó L
Metab Syndr Relat Disord; 2019 Jun; 17(5):289-295. PubMed ID: 31013454
[No Abstract] [Full Text] [Related]
2. Effects of Oral Antidiabetic Drugs on Changes in the Liver-to-Spleen Ratio on Computed Tomography and Inflammatory Biomarkers in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
Yabiku K; Mutoh A; Miyagi K; Takasu N
Clin Ther; 2017 Mar; 39(3):558-566. PubMed ID: 28185715
[TBL] [Abstract][Full Text] [Related]
3. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study.
Shibuya T; Fushimi N; Kawai M; Yoshida Y; Hachiya H; Ito S; Kawai H; Ohashi N; Mori A
Diabetes Obes Metab; 2018 Feb; 20(2):438-442. PubMed ID: 28719078
[TBL] [Abstract][Full Text] [Related]
4. Transabdominal ultrasonography of the pancreas is superior to that of the liver for detection of ectopic fat deposits resulting from metabolic syndrome.
Li S; Su L; Lv G; Zhao W; Chen J
Medicine (Baltimore); 2017 Sep; 96(37):e8060. PubMed ID: 28906401
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
Li X; Wu X; Jia Y; Fu J; Zhang L; Jiang T; Liu J; Wang G
J Diabetes Res; 2021; 2021():3715026. PubMed ID: 34660809
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic Fatty Pancreas Disease: Role in Metabolic Syndrome, "Prediabetes," Diabetes and Atherosclerosis.
Filippatos TD; Alexakis K; Mavrikaki V; Mikhailidis DP
Dig Dis Sci; 2022 Jan; 67(1):26-41. PubMed ID: 33469809
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease.
Feng W; Gao C; Bi Y; Wu M; Li P; Shen S; Chen W; Yin T; Zhu D
J Diabetes; 2017 Aug; 9(8):800-809. PubMed ID: 28332301
[TBL] [Abstract][Full Text] [Related]
8. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
Kuchay MS; Krishan S; Mishra SK; Farooqui KJ; Singh MK; Wasir JS; Bansal B; Kaur P; Jevalikar G; Gill HK; Choudhary NS; Mithal A
Diabetes Care; 2018 Aug; 41(8):1801-1808. PubMed ID: 29895557
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies.
Tang W; Xu Q; Hong T; Tong G; Feng W; Shen S; Bi Y; Zhu D
Diabetes Metab Res Rev; 2016 Feb; 32(2):200-16. PubMed ID: 26381272
[TBL] [Abstract][Full Text] [Related]
10. Comparison between the effect of Empagliflozin and Pioglitazone added to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Hooshmand Gharabagh L; Shargh A; Mohammad Hosseini Azar MR; Esmaeili A
Clin Res Hepatol Gastroenterol; 2024 Mar; 48(3):102279. PubMed ID: 38159676
[TBL] [Abstract][Full Text] [Related]
11. Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD).
Doycheva I; Loomba R
Adv Ther; 2014 Jan; 31(1):30-43. PubMed ID: 24385405
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic fatty pancreas disease and Nonalcoholic fatty liver disease: more than ectopic fat.
Della Corte C; Mosca A; Majo F; Lucidi V; Panera N; Giglioni E; Monti L; Stronati L; Alisi A; Nobili V
Clin Endocrinol (Oxf); 2015 Nov; 83(5):656-62. PubMed ID: 26201937
[TBL] [Abstract][Full Text] [Related]
13. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes.
Markova M; Pivovarova O; Hornemann S; Sucher S; Frahnow T; Wegner K; Machann J; Petzke KJ; Hierholzer J; Lichtinghagen R; Herder C; Carstensen-Kirberg M; Roden M; Rudovich N; Klaus S; Thomann R; Schneeweiss R; Rohn S; Pfeiffer AF
Gastroenterology; 2017 Feb; 152(3):571-585.e8. PubMed ID: 27765690
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone compared with metformin increases pericardial fat volume in patients with type 2 diabetes mellitus.
Jonker JT; Lamb HJ; van der Meer RW; Rijzewijk LJ; Menting LJ; Diamant M; Bax JJ; de Roos A; Romijn JA; Smit JW
J Clin Endocrinol Metab; 2010 Jan; 95(1):456-60. PubMed ID: 19915017
[TBL] [Abstract][Full Text] [Related]
15. [Effect of metformin on the expression of SIRT1 and UCP2 in rat liver of type 2 diabetes mellitus and nonalcoholic fatty liver].
Xu J; Li N; Wang J; Zhang C; Ding S; Jiao Y; Zhang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 38(9):882-7. PubMed ID: 24071688
[TBL] [Abstract][Full Text] [Related]
16. Metformin: An Old Drug with New Applications.
Zhou J; Massey S; Story D; Li L
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30241400
[TBL] [Abstract][Full Text] [Related]
17. Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?
Mazzotti A; Caletti MT; Marchignoli F; Forlani G; Marchesini G
Dig Liver Dis; 2017 Mar; 49(3):235-240. PubMed ID: 28089623
[TBL] [Abstract][Full Text] [Related]
18. Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: A prospective study.
Brouha SS; Nguyen P; Bettencourt R; Sirlin CB; Loomba R
Eur Radiol; 2018 Apr; 28(4):1345-1355. PubMed ID: 29058029
[TBL] [Abstract][Full Text] [Related]
19. Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis?
Green CJ; Marjot T; Tomlinson JW; Hodson L
Diabetes Obes Metab; 2019 Apr; 21(4):749-760. PubMed ID: 30456918
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease.
Handzlik G; Holecki M; Kozaczka J; Kukla M; Wyskida K; Kędzierski L; Pawlicki K; Duława J
Pharmacol Rep; 2019 Apr; 71(2):183-188. PubMed ID: 30780126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
